Literature DB >> 14657089

The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden.

Julian G Hurdle1, Alex J O'Neill, Ian Chopra.   

Abstract

OBJECTIVES AND METHODS: Failure to eradicate nasal carriage of a glycopeptide-intermediate Staphylococcus aureus (strain GISA-2) with mupirocin was recently attributed to a mutation that confers low-level mupirocin resistance. To identify this mutation the ileS genes of GISA-2 and its mupirocin-susceptible progenitor GISA-1 were sequenced. For comparison, the ileS genes of 10 laboratory-derived mupirocin-resistant mutants of the GISA strain Mu50 were also examined. The fitness of GISA-2 and mupirocin-susceptible GISA-1, as well as Mu50 and its mupirocin-resistant derivatives, were compared by evaluation of growth rates and performance in mixed-culture competition assays.
RESULTS: The point mutation V588F in the isoleucyl-tRNA synthetase was identified from the ileS sequences of GISA-2 and mupirocin-resistant mutants of Mu50. The V588F mutation was not associated with a significant fitness burden.
CONCLUSIONS: The low fitness cost of the V588F substitution in isoleucyl-tRNA synthetase is consistent with the frequent appearance and maintenance of this mutation in mupirocin-resistant clinical isolates, including GISA-2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657089     DOI: 10.1093/jac/dkh020

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

Review 1.  Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

Authors:  A J O'Neill; T Huovinen; C W G Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Genome sequence of a recently emerged, highly transmissible, multi-antibiotic- and antiseptic-resistant variant of methicillin-resistant Staphylococcus aureus, sequence type 239 (TW).

Authors:  Matthew T G Holden; Jodi A Lindsay; Craig Corton; Michael A Quail; Joshua D Cockfield; Smriti Pathak; Rahul Batra; Julian Parkhill; Stephen D Bentley; Jonathan D Edgeworth
Journal:  J Bacteriol       Date:  2009-11-30       Impact factor: 3.490

4.  Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase.

Authors:  Katherine Mariner; Martin McPhillie; Rachel Trowbridge; Catriona Smith; Alex J O'Neill; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

Review 5.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

Review 6.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

7.  Targeting Multiple Aminoacyl-tRNA Synthetases Overcomes the Resistance Liabilities Associated with Antibacterial Inhibitors Acting on a Single Such Enzyme.

Authors:  Christopher P Randall; Dace Rasina; Aigars Jirgensons; Alex J O'Neill
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Authors:  Mark S Rouse; Margalida Rotger; Kerryl E Piper; James M Steckelberg; Matthew Scholz; Jeffrey Andrews; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis.

Authors:  Julian G Hurdle; Alex J O'Neill; Lona Mody; Ian Chopra; Suzanne F Bradley
Journal:  J Antimicrob Chemother       Date:  2005-11-07       Impact factor: 5.790

10.  Evolution of MRSA during hospital transmission and intercontinental spread.

Authors:  Simon R Harris; Edward J Feil; Matthew T G Holden; Michael A Quail; Emma K Nickerson; Narisara Chantratita; Susana Gardete; Ana Tavares; Nick Day; Jodi A Lindsay; Jonathan D Edgeworth; Hermínia de Lencastre; Julian Parkhill; Sharon J Peacock; Stephen D Bentley
Journal:  Science       Date:  2010-01-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.